Revance Therapeutics (RVNC) to Offer $150M in Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Revance Announces Proposed Public Offering of Common Stock
September 12, 2022 4:01 PM EDTNASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (Revance or the Company), today announced a proposed underwritten public offering of $150 million of its common stock. In addition, Revance expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. The Company intends to use the net proceeds from the offering to fund the commercialization of DAXXIFY, the RHA® Collection of dermal fillers and OPUL®, and for working capital,... More
